Short Interest in Chimerix, Inc. (NASDAQ:CMRX) Decreases By 12.6%

Chimerix, Inc. (NASDAQ:CMRX) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,520,000 shares, a decrease of 12.6% from the October 15th total of 1,740,000 shares. Based on an average trading volume of 460,100 shares, the days-to-cover ratio is presently 3.3 days. Approximately 1.9% of the company’s stock are sold short.

Chimerix Price Performance

Shares of NASDAQ:CMRX traded down $0.04 during midday trading on Friday, reaching $0.86. The company had a trading volume of 689,133 shares, compared to its average volume of 250,829. Chimerix has a one year low of $0.75 and a one year high of $1.30. The stock has a market capitalization of $77.34 million, a P/E ratio of -0.91 and a beta of 1.13. The stock’s fifty day moving average price is $0.90 and its 200-day moving average price is $0.91.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CMRX shares. Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, November 7th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research note on Monday, November 11th.

Institutional Investors Weigh In On Chimerix

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in Chimerix in the second quarter worth about $137,000. Valeo Financial Advisors LLC lifted its holdings in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Koshinski Asset Management Inc. acquired a new stake in shares of Chimerix during the 1st quarter valued at approximately $42,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.